EXELEAD
Exelead is a dynamic platform that develops and produces liposomal and LNP drug product formulations. Founded in 2017, the company specializes in manufacturing lipid nanoparticle, liposome, and pegylation formulations. Exelead is a wholly-owned subsidiary of Essetifin SpA in Rome, Italy—a privately owned pharmaceutical company specializing in Rare Diseases and Orphan Drugs.
EXELEAD
Social Links:
Industry:
Biotechnology Health Care Manufacturing Pharmaceutical
Founded:
2017-01-01
Address:
Indianapolis, Indiana, United States
Country:
United States
Website Url:
http://www.exeleadbiopharma.com
Total Employee:
101+
Status:
Active
Contact:
+1 317-347-2800
Similar Organizations
Welmedix Consumer Healthcare
Welmedix Consumer Healthcare develops and markets pharmaceutical products.
Biotix
Biotix is a manufacturer of laboratory consumable tools and liquid handling solutions.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Polymate
Polymate Ltd is a research facility that develops hybrid polyurethane materials and fire protective coatings.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Current Employees Featured
Official Site Inspections
http://www.exeleadbiopharma.com Semrush global rank: 7.6 M Semrush visits lastest month: 456
Unable to get host informations!!!
More informations about "Exelead"
Exelead - Crunchbase Company Profile & Funding
Commercial Contract Manufacturing: Exelead offers commercial manufacturing services for sterile products, specializing in complex biological and liposomal formulations, with capabilities for …See details»
Exelead Company Profile | Management and Employees List
Www.exeleadbiopharma.com Exelead Profile and History Exelead has more than ten years of experience in all development phases from pre-clinical development to commercial contract …See details»
Exelead Acquisition | Merck
Feb 23, 2022 The business combination is expected to enable Merck’s Life Science business sector to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services …See details»
Definitive Agreement to Acquire Exelead will Strengthen Merck’s …
Contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash. Exelead specializes in complex injectable formulations, including Lipid …See details»
Exelead 2025 Company Profile: Valuation, Investors, …
Exelead General Information Description. Developer of liquid injectables for rare diseases or small populations intended to save lives. The company specializes in manufacturing lipid nanoparticles, liposomes and pegylation formulations, …See details»
Exelead - Overview, News & Similar companies | ZoomInfo.com
Jan 5, 2022 Exelead contact info: Phone number: (317) 347-2800 Website: www.exeleadbiopharma.com What does Exelead do? Exelead has more than ten years of …See details»
Definitive Agreement to Acquire Exelead will …
Burlington, MA, January 6, 2022 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to …See details»
Exelead Inc. Company Profile | Indianapolis, IN | Competitors ...
Find company research, competitor information, contact details & financial data for Exelead Inc. of Indianapolis, IN. Get the latest business insights from Dun & Bradstreet.See details»
Exelead Biopharma a MilliporeSigma company - PharmaSource
Exelead Biopharma a MilliporeSigma company continues to support the pharmaceutical industry with its extensive range of services designed to meet the evolving needs of drug development …See details»
Exelead Biopharma a MilliporeSigma company Indianapolis, IN, USA
Https://exeleadbiopharma.com. 6925 Guion Rd Indianapolis, IN, 46268 USA 6.6. High (2) Leave a Review Claim Listing Categories. Fill-Finish and Formulation; Lipid Excipient Supplier; Lipid …See details»
Definitive Agreement Exelead - News | Merck
Jan 6, 2022 Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 …See details»
Exelead - VentureRadar
Curapath Spain n/a Curapath is a leading Contract Development and Manufacturing Organization (CDMO) specializing in polymers, lipids, and non-viral nano carriers. Renowned for their …See details»
Exelead Management Team | Org Chart - RocketReach
Exeleadbiopharma.com; 2 317612XXXX; 765378XXXX; Dawn Schneider QC Chemistry Manager at Exelead Mooresville, IN, US View. 2 ... Suburban Health Organization. 37 $6m NICO …See details»
MilliporeSigma Renewable Energy Initiative
Darmstadt, Germany, February 23, 2022 – MilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology …See details»
Merck KGaA to acquire Exelead in $780m deal - BioProcess Insider
Jan 7, 2022 Merck will strengthen its mRNA offerings within its biopharma services division MilliporeSigma after signing a definitive agreement to acquire contract development …See details»
Exelead Overview | SignalHire Company Profile
Scientists are driven by powerful ideas to develop innovative molecules that can save lives. But to bring their drug to market, they must navigate pharmaceutical manufacturing, clinical trials, …See details»
Definitive Agreement Exelead - News | Merck KGaA, Darmstadt, …
Jan 6, 2022 Merck KGaA, Darmstadt, Germany, announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing …See details»
Another mRNA company gets snapped up as Merck buys Exelead
3 days ago The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Unlike …See details»
Merck signs agreement to acquire Exelead for $780m
Jan 7, 2022 Merck Executive Board chair and CEO Belén Garijo said: “Novel modalities, particularly mRNA, present a highly attractive business opportunity as pharma and biotech …See details»
Definitive Agreement to Acquire Exelead will Strengthen Merck’s …
Darmstadt, Germany, January 6, 2022 – Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development …See details»